The Danish drugmaker sued Hims in February over compounded versions of the Wegovy weight-loss pill that Hims launched and ...

Novo Nordisk and Hims & Hers have come to an agreement that will see the telehealth company sell Novo’s branded glucagon-like peptide-1 receptor agonists (GLP-1RAs), ending a long-running feud that ...

Hims & Hers Health partners with Novo Nordisk to sell weight loss medications, ending patent lawsuit. Shares surge 40% as companies reach agreement on Wegovy and Ozempic distribution.

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (HIMS +5.89%), an estimated $18.07 million trade based on quarterly ...

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop ...

After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker ...

Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.

Shares of Hims & Hers Health (NYSE: HIMS) skyrocketed after the telemedicine platform came to an agreement with Novo Nordisk (NYSE: NVO) to sell the drugmaker's popular GLP-1 weight loss drugs. The ...

Hims & Hers Health Inc was upgraded to “Neutral” from “Underperform” by Bank of America, which said a new agreement with Novo Nordisk removes a key legal risk that had weighed on the telehealth ...

Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved versions of Ozempic and Wegovy at self‑pay prices comparable to other digital ...

Novo Nordisk drops patent lawsuit against Hims & Hers after agreement to sell branded weight loss medicines on Hims platform. Shares of Hims & Hers jump 36%.